These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16143737)

  • 41. Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis.
    Silva MT; Zimmermann IR; Galvao TF; Pereira MG
    J Affect Disord; 2013 Apr; 146(3):310-8. PubMed ID: 23218251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can olanzapine be implicated in causing serotonin syndrome?
    Haslett CD; Kumar S
    Psychiatry Clin Neurosci; 2002 Oct; 56(5):533-5. PubMed ID: 12193243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data.
    Vieta E; Calabrese JR; Hennen J; Colom F; Martínez-Arán A; Sánchez-Moreno J; Yatham LN; Tohen M; Baldessarini RJ
    J Clin Psychiatry; 2004 Oct; 65(10):1420-8. PubMed ID: 15491248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case of bipolar disorder and typhoid fever.
    Santangelo CG; Goldstein D; Green S
    Int J Psychiatry Med; 2004; 34(3):267-9. PubMed ID: 15666961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():86-7. PubMed ID: 14579491
    [No Abstract]   [Full Text] [Related]  

  • 46. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
    Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
    Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Long-term therapy with intuition].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():87. PubMed ID: 14579492
    [No Abstract]   [Full Text] [Related]  

  • 49. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
    Dubé S; Tollefson GD; Thase ME; Briggs SD; Van Campen LE; Case M; Tohen M
    Bipolar Disord; 2007 Sep; 9(6):618-27. PubMed ID: 17845277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
    Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
    Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delirium Associated With Fluoxetine Discontinuation: A Case Report.
    Fan KY; Liu HC
    Clin Neuropharmacol; 2017; 40(3):152-153. PubMed ID: 28452902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
    Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF
    J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report.
    Aldurra G; Crayton JW
    J Clin Psychopharmacol; 2001 Jun; 21(3):343-4. PubMed ID: 11386500
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical relevance of depressive symptom improvement in bipolar I depressed patients.
    Williamson D; Brown E; Perlis RH; Ahl J; Baker RW; Tohen M
    J Affect Disord; 2006 Jun; 92(2-3):261-6. PubMed ID: 16563521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment options for bipolar depression.
    Bowden CL
    J Clin Psychiatry; 2005; 66 Suppl 1():3-6. PubMed ID: 15693745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving identification of treatment effectiveness in bipolar disorders.
    Bowden CL
    Bipolar Disord; 2003 Apr; 5(2):77-8. PubMed ID: 12680895
    [No Abstract]   [Full Text] [Related]  

  • 57. Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine.
    Chand PK; Anand S; Murthy P
    J Clin Psychiatry; 2005 Jun; 66(6):800-1. PubMed ID: 15960578
    [No Abstract]   [Full Text] [Related]  

  • 58. A novel augmentation strategy for treating resistant major depression.
    Shelton RC; Tollefson GD; Tohen M; Stahl S; Gannon KS; Jacobs TG; Buras WR; Bymaster FP; Zhang W; Spencer KA; Feldman PD; Meltzer HY
    Am J Psychiatry; 2001 Jan; 158(1):131-4. PubMed ID: 11136647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
    Cruz N; Sanchez-Moreno J; Torres F; Goikolea JM; Valentí M; Vieta E
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):5-14. PubMed ID: 19638254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.
    Perlis RH; Adams DH; Fijal B; Sutton VK; Farmen M; Breier A; Houston JP
    J Clin Psychiatry; 2010 May; 71(5):599-605. PubMed ID: 20021991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.